Compositions for treating macular edema
This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.
1. A method of treating macular edema in an individual in need thereof, comprising administering to the individual by intravitreous injection, an oncotic pressure-increasing macromolecule having a molecular weight of 25 kDa or more and which does not recognize VEGF, as the sole active ingredient, wherein the oncotic pressure-increasing macromolecule is a protein macromolecule consisting of gelatin.
2. The method according to claim 1 , wherein the protein macromolecule is gelatin in a 2%-10% w/w gelatin composition.
3. The method according to claim 1 , wherein the oncotic pressure-increasing macromolecule is in a composition adapted for dosage units having a volume ranging from 10 μl to 500 μl.
4. A method of treating a macular edema disorder in an individual in need thereof, comprising administering to the individual by intravitreous injection, an oncotic pressure-increasing macromolecule having 25 kDa or more and which does not recognize VEGF, as the sole active ingredient, wherein the oncotic pressure-increasing macromolecule is a protein macromolecule consisting of gelatin, and wherein the macular edema disorder is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, uveitis, retinal vein occlusion, retinitis pigmentosa and pseudophakic macular edema.